- Features detailed information on the latest translational studies on PARP inhibitors
- Contains 'key points' and 'expert opinion points' sections in each chapter for greater emphasis
- Provides detailed insight into preclinical/clinical development of rational combination studies for PARP inhibitors
This book discusses the latest developments in Poly (ADP-ribose) polymerase (PARP) inhibitor drug development.
It focuses on the translational and clinical development of the latest drugs, as well as the evidence for regulatory approval of PARP inhibitors in multiple different molecular subtypes and tumor indications.
The most-up-to-date information on basic scientific research on DNA repair pathways and the DNA Damage Response (DDR) is also covered. Every chapter contains insight into the preclinical, translational along with clinical aspects of a specific DDR inhibitor with key and expert opinion points reinforcing the most important concepts detailed to enable the reader to develop a deep understanding of the topic.
Targeting the DNA Damage Response for Cancer Therapy comprehensively reviews the application of PARP and other DDR inhibitors across oncology disciplines. Therefore, it is a valuable resource for all medical professionals and researchers who use or who are researching the use of these inhibitors on a day-to-day basis.
Table of Contents- Evolution of the development of PARP inhibitors.-
- Exploiting cancer synthetic lethality in cancer - Lessons learnt from PARP inhibitors.-
- Mechanisms of PARP inhibitor resistance.-
- Development of homologous recombination functional assays for targeting the DDR.-
- Clinical application of Poly(ADP Ribose) Polymerase (PARP) inhibitors in ovarian cancer.-
- Clinical use of PARP inhibitors in BRCA mutant and non-BRCA mutant breast cancer.-
- Development of PARP inhibitors in targeting castration-resistant prostate cancer.-
- Strategies for the management of patients with pancreatic cancer with PARP inhibitors.-
- Combining poly (ADP-ribose) polymerase (PARP) inhibitors with chemotherapeutic agents: Promise and challenges.-
- Rational combinations of PARP inhibitors with HRD-inducing molecularly targeted agents.-
- Combining PARP inhibition and immunotherapy in BRCA-associated cancers.-
- Targeting MTH1 in treatment of cancer.-
- Targeting ATR in cancer medicine.-
- Targeting polymerase Theta (POLq) for cancer therapy.-
- Targeting DNA-PK.-
- WRN is a promising synthetic lethal target for cancers with microsatellite instability (MSI).
